Clinical trials for cancer patients
The Clínica is the private center that promotes the most clinical trials in Spain. We aim to generate knowledge to change the course of diseases.
-
July 2, 2026Pamplona/MadridIn recruitment
CA254-0001 Phase 1/2a, first-in-human, open-label clinical trial of BMS-986517 as monotherapy in adult participants with advanced solid tumors.
This study is designed to help us determine whether the study drug BMS-986517 works to treat advanced solid tumors. Experts are continuing to investigate BMS-986517 to learn about its side effects and efficacy. The study drug has not yet been approved by the Food and Drug Administration (FDA) or other regulatory agencies for the treatment of advanced solid tumors or any other medical condition. -
June 25, 2026Pamplona/MadridIn recruitmentEarly phase
M-2020-371 Clinical trial of MB-CART2019.1 compared with standard of care in participants with relapsed/refractory diffuse large B-cell lymphoma.
The objective of this study is to determine whether an investigational drug called MB-CART2019.1 is more effective than a second standard chemotherapy treatment for your disease. This study will also investigate the safety of MB-CART2019.1 when administered to patients and will determine whether there are any changes in their quality of life. -
June 15, 2026Pamplona/MadridIn recruitmentEarly phase
CTL-002-003 A randomized, double-blind, phase 2b comparative clinical trial investigating the efficacy and safety of visugromab compared with placebo
The objective of this study is to determine the safety and efficacy of a new drug called “visugromab” when administered in combination with immunochemotherapy -
June 15, 2026PamplonaIn recruitment
C1071015 A TRIAL FOR PARTICIPANTS WITH MULTIPLE MYELOMA WHO HAVE PARTICIPATED IN PFIZER-SPONSORED CLINICAL TRIALS OF ELRANATAMAB
The objective of this study is to provide continued access to elranatamab (as monotherapy) and to monitor the safety of this drug in participants with multiple myeloma who continue to show clinical benefits in the Pfizer-sponsored main study, which is scheduled to conclude. -
June 10, 2026PamplonaIn recruitment
22931 Clinical trial conducted in humans to evaluate the safety of BAY 3713372 and how it works in participants with solid tumors with MTAP gene deletion
The aim of this trial is: -To see whether the new treatment BAY 3713372 has any effect, good or bad. -To find the best dose of BAY 3713372 to give to participants. -To understand what happens to BAY 3713372 once it is in the body. -To understand how the drug affects your body. -To understand how the treatment affects your disease. -To learn how different types and amounts of food affect the way the body absorbs the trial drug. -
June 10, 2026Pamplona/MadridIn recruitmentEarly phase
M25-279 Phase II clinical study to evaluate the safety and efficacy of Telisotuzumab Adizutecan in the treatment of subjects with locally advanced or metastatic solid tumors with MET amplification.
The aim of this study is to evaluate the efficacy, safety and tolerability of Temab-A as monotherapy in patients with locally advanced or metastatic solid tumors with MET gene amplification. -
June 10, 2026Pamplona/MadridIn recruitmentEarly phase
CTL-002-004 Randomized, blinded, placebo-controlled phase 2 clinical trial investigating the efficacy and safety of visugromab and nivolumab, with or without docetaxel, compared with docetaxel alone.
The aim of this clinical trial is to determine the efficacy of a new drug called “visugromab” (also known as “CT-L002”) and its safety when administered in combination with nivolumab and docetaxel. CT-L002 and nivolumab help the immune system fight cancer. Docetaxel interferes with the growth of cancer cells, leading to their destruction. CT-L002 has not yet been approved for any patients outside research studies. -
June 8, 2026Pamplona/MadridIn recruitmentEarly phase
CTL-002-005 A clinical trial investigating the efficacy and safety of visugromab in combination with nivolumab and lenvatinib compared with a double-blind placebo and lenvatinib in participants with unresectable or metastatic hepatocellular carcinoma and ....
The purpose of this trial is to determine how well a new drug currently in development called visugromab (also known as CTL-002) works and whether it is safe when used in combination with nivolumab and lenvatinib. -
June 2, 2026Pamplona/MadridIn recruitment
STK-012-101 Phase I/II study of STK-012 as monotherapy and in combination therapy in solid tumors.
The primary objective of this study is to determine whether STK-012 administered together with standard-of-care treatment is more effective in treating cancer than standard-of-care treatment alone in patients with lung cancer. STK-012 is a new investigational drug being studied by the sponsor. -
June 2, 2026PamplonaIn recruitment
LB208-1-002 Multicenter, open-label, phase I/II study of LB-208, a selective antagonist of the 5-hydroxytryptamine serotonin receptor 1B (HTR1B), in adults with relapsed or refractory (r/r) acute myeloid leukemia (AML) and high-risk (HR) relapsed or refractory (r/r) myelodysplastic syndrome (MDS).
The objective of this trial, which involves research, is to examine the safety and efficacy of an investigational drug called LB-208. Investigational means that the investigational drug to be tested in this clinical trial has not been authorized by national drug regulatory agencies, such as the Spanish Agency of Medicines and Medical Devices.